Status: current, Sufficiently defined by necessary conditions definition status (core metadata concept). Date: 31-Jul 2018. Module: SNOMED CT core
Descriptions:
| Id | Description | Lang | Type | Status | Case? | Module |
| 3700068014 | Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | en | Fully specified name | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3700069018 | Scopolamine hydrobromide 300 microgram oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| 3700070017 | Hyoscine hydrobromide 300 microgram oral tablet | en | Synonym (core metadata concept) | Active | Entire term case insensitive (core metadata concept) | SNOMED CT core |
| Outbound Relationships | Type | Target | Active | Characteristic | Refinability | Group | Values |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Scopolamine hydrobromide | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has active ingredient | Scopolamine (substance) | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Tablet | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine hydrobromide | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has active ingredient | Scopolamine hydrobromide (substance) | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Scopolamine hydrobromide | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has manufactured dose form | Oral tablet | true | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine-containing product in oral dose form | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has active ingredient | Scopolamine hydrobromide (substance) | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has basis of strength substance (attribute) | Scopolamine hydrobromide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 300 | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | mcg | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator value | 1 | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength denominator unit (attribute) | Tablet (unit of presentation) | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator value | 0.3 | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has presentation strength numerator unit | mg | false | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has precise active ingredient | Scopolamine hydrobromide (substance) | true | Inferred relationship | Some | 1 | |
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Has unit of presentation | Tablet (unit of presentation) | true | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Count of base of active ingredient | 1 | false | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Is a | Hyoscine only product in oral dose form | true | Inferred relationship | Some | ||
| Product containing precisely scopolamine hydrobromide 300 microgram/1 each conventional release oral tablet (clinical drug) | Plays role | Antiemetic therapeutic role (role) | false | Inferred relationship | Some |
| Inbound Relationships | Type | Active | Source | Characteristic | Refinability | Group |
This concept is not in any reference sets
FHIR